Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibody therapeutics - Kymab

Next Previous
Drug Profile

Research programme: monoclonal antibody therapeutics - Kymab

Alternative Names: Anti-OPG Antibody; KY 1003; KY 1006; KY 1007; KY 1009; KY 1015; KY 1016; KY 1017; KY 1020; KY 1021; KY 1031; KY 1034; KY 1040; KY 1041; KY 1047; KY 1050; KY 1055; KY 1081; KY 7001; KY 7002; KY 7003; KY 7004; KY 7005; KY 7006; Ky3

Latest Information Update: 28 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kymab
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Immunostimulants; Inducible T-cell co-stimulator protein antagonists; Programmed cell death-1 ligand-1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer; Haematological disorders; Inflammatory bowel diseases; Pulmonary hypertension; Systemic lupus erythematosus
  • Discontinued Cardiovascular disorders; Dyslipidaemias; Fibrosis; Graft-versus-host disease; Infections; Pain

Most Recent Events

  • 28 May 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom (Parenteral)
  • 28 Dec 2021 No recent reports of development identified for preclinical development in Pulmonary-hypertension in United Kingdom (Parenteral)
  • 09 Apr 2021 Kymab has been acquired by Sanofi

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top